Corrigendum to “Identification of Differential Tumor Subtypes of T1 Bladder Cancer” [Eur. Urol. 78 (2020) 533–537] (European Urology (2020) 78(4) (533–537), (S030228382030508X), (10.1016/j.eururo.2020.06.048))

A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, Xiaoqi Lin, Kimberly A. McLaughlin, Arighno Das, Leigh Ann Fall, Damiano Fantini, Timothy J. Taxter, Lauren S. Mogil, Sia Viborg Lindskrog, Lars Dyrskjøt, David J. McConkey, Robert S. Svatek, Aurélien de Reyniès, Mauro A.A. Castro, Joshua J. Meeks

Producción científica: Comment/debaterevisión exhaustiva

Resumen

In the original article, the name of author Xiaoqi Lin was incorrectly given as Xiquo Lin. Conflicts of interest: Joshua J. Meeks is a consultant for Ferring, AstraZeneca, and Janssen and has participated in advisory boards for Foundation Medicine and Nucleix. The remaining authors have nothing to disclose.

Idioma originalEnglish (US)
Páginas (desde-hasta)e53
PublicaciónEuropean Urology
Volumen81
N.º2
DOI
EstadoPublished - feb 2022

ASJC Scopus subject areas

  • Urology

Huella

Profundice en los temas de investigación de 'Corrigendum to “Identification of Differential Tumor Subtypes of T1 Bladder Cancer” [Eur. Urol. 78 (2020) 533–537] (European Urology (2020) 78(4) (533–537), (S030228382030508X), (10.1016/j.eururo.2020.06.048))'. En conjunto forman una huella única.

Citar esto